Nexell Therapeutics Inc.
- Share via
The Irvine supplier of therapeutic and diagnostic products posted a second-quarter net loss of $10 million, or 14 cents a share, compared with a net loss of $10.3 million, or 15 cents a share, for the same period last year. Revenue dropped 52% to $1.6 million. The company attributed the sales decline to the repurchase of inventory from Baxter Healthcare Corp.
More to Read
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
